Dr Reddy’s launches oral semaglutide in India

Dr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three tablet strengths for daily use. This launch expands access to advanced diabetes care. Dr Reddys is the second Indian company to introduce oral semaglutide domestically. The company is committed to reliable supply and consistent quality for Indian patients.